Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 11, 2013, Pages 1937-1946

  Pönisch, Wolfram ^a   Moll, Barbara ^a   Bourgeois, Malvina ^a   Andrea, Marc ^a   Schliwa, Thomas ^a   Heyn, Simone ^a   Schmalfeld, Marion ^b   Edelmann, Thomas ^c   Becker, Cornelia ^a   Hoffmann, Franz Albert ^d   Schwarzer, Andreas ^d   Kreibich, Ute ^e   Egert, Matthias ^d   Stiegler, Runa ^b   Krahl, Rainer ^a   Remane, Yvonne ^a   Bachmann, Anette ^a   Lindner, Tom ^a   Weidhase, Lorenz ^a   Petros, Sirak ^a   Fricke, Stefan ^a   Vucinic, Vladan ^a   Al Ali, Haifa ^a   Niederwieser, Dietger ^a   more..

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Innere Med IV/Universitatklinikum   (Germany)

^c Medcenter Nordsachsen   (Germany)

^d Praxis für Hämatologie Onkologie Dr Aldaoud   (Germany)

^e Heinrich Braun Krankenhaus   (Germany)

Author keywords

Advanced renal failure; Bendamustine; Bortezomib; Prednisone; Relapsed refractory multiple myeloma

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PYRAZINE DERIVATIVE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EMBOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; CANCER STAGING; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PREDNISONE; PYRAZINES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84892674918     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1513-2     Document Type: Article

References (36)

1. Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695
2. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321-330
3. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ (2008) Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 6:352-355
4. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604-2606
5. Clark AD, Shetty A, Soutar R (1999) Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 13(2):79-90
6. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493
7. Dimopoulos MA, Roussou M, Gavriatopoulou M (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors. Clin Lymphoma Myeloma 9:302-306
8. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand J-P, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau J-L, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Gavo M, Rajkumar SV, Durie BGM, Miguel JS (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol 28:4976-4984
9. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854
10. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473
11. Field-Smith A, Morgan GJ, Davies FE (2006) Bortezomib (Velcade TM) in the treatment of multiple myeloma. Ther Clin Risk Manag 2:271-279
12. FischerK,Cramer P,BuschR, Stilgenbauer S,Bahlo J, SchweighoferCD, Böttcher S, Staib P,Kiehl M, Eckart MJ,KranzG,GoedeV, Elter T, Bühler A,WinklerD,KnebaM,DöhnerH, Eichhorst BF,HallekM, Wendtner CM (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 29:3559-3566
13. Gandhi V (2002) Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 29(Suppl. 13):4-11
14. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Muller C, Muller C (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO # 19). J Cancer Res Clin Oncol 132:105-112
15. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(26):4378-4384
16. Knop S, Straka C, HaenM, Schwedes R, Hebart H, Einsele H (2005) The efficacy and toxicity of bendamustine in recurrentmultiplemyeloma after high-dose chemotherapy. Haematologica 90:1287-1288
17. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serumcreatinine: a new prediction equation.Modification of diet in renal disease study group. Ann Intern Med 130:461-470
19. Ludwig H, Drach J, Graf H, Lang A, Meran JG (2007a) Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92:1411-1414
20. Ludwig H, Adam Z, Hajek R, Greil R, Keil F, Zojer N, Thaler J, Gisslinger H, Lang A (2007b) Recovery of renal impairment by bortezomib-doxorubicin- dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results of an ongoing phase II study. Blood 110:3603
21. Ludwig H, Pour L, Kasparu H, Greil R, Linkesch W, Thaler J, Leitgeb C, Rauch E, Heintel D, Zojer N, Weissmann A, Adam Z (2012) Bortezomib-bendamustine- dexamethasone (BBD) in patients with relapsed/refractory myeloma and different risk profiles namely, cytogenetics, previous exposure to bortezomib or to lenalidomide. Haematologica 97(e-Supplement 1):408-409
22. Offidani M, Corvatta L, Caraffa P, Liberati AM, Alesiani F, Brunori M, Caravita Di Toritto T, Gentili S, Attolico I, Mele A, Pulini S, Ballanti S, Galimberti S, Gozzetti A, Coppetelli U, Ledda A, Leoni P (2012) Bendamustine, bortezomib and dexamethasone (BVD) combination for the treatment of relapsed/refractory multiple myeloma: an interim analysis of a phase II study. Haematologica 97(e-Supplement 1):415
23. Pönisch W, Niederwieser D (2002) Bendamustine in the treatment of multiple myeloma: results and future perspectives. Semin Oncol 29(4 Suppl 13):23-26
24. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German study group of haematology and oncology (OSHO). J Cancer Res Clin Oncol 132:205-212
25. Pönisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012) Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138:1405-1412
26. Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, AL-Ali H, Niederwieser D (2013) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499-508
27. Preiss R, Teichert J, Pönisch W, Niederwieser D, Matthias M, Merkle KH (2003) Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease. Hematol J 4(Suppl. 1):263
28. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S (2011) Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 155:632-634
29. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
30. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
31. Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa A, Traullé C, Vilque J,Moreau P,MathiotC,Avet-Loiseau H (2012) Bendamustine, bortezomib and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma: The Intergroupe francophone du myelome (IFM) 2009-01 protocol. Haematologica 97(e-Supplement 1):400-401
32. Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Psimenou E, Grapsa I, Matsouka C, Gika D, Barmparousi D, Terpos E, Dimopoulos MA (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49:890-895
33. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E, Dimopoulos MA (2010) Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34:1395-1397
34. RummelMJ,NiederleN,MaschmeyerGA, vonGrünhagen U, LosemC, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, HoelzerD,HinkeA, BruggerW; Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203-1210
35. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, BoralAL, EsseltineDL,AndersonKC(2008) Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22:842-849
36. Terpos E, Cibeira MT, Blade J, Ludwig H (2009) Management of complications in multiple myeloma. Semin Hematol 46:176-189